PDA is a non-profit international association of more than 10,500 scientists involved in the development, manufacture, quality control and regulation of pharmaceuticals/biopharmaceuticals and related products. The association also provides educational opportunities for government and university sectors that have a vocational interest in pharmaceutical/biopharmaceutical sciences and technology.
The mission of PDA is to advance pharmaceutical and biopharmaceutical technology internationally by promoting scientifically sound and practical technical information and education for industry and regulatory agencies.
In addition to sponsoring education conferences and courses, PDA publishes the PDA Journal of Pharmaceutical Science and Technology and the PDA Letter that focuses on industry and regulatory news. In keeping with its fifty-year history of promoting the growth of pharmaceutical science and technology, PDA introduced its latest contribution, the PDA Training and Research Institute (PDA-TRI), in May 1997.
PDA was founded in 1946 as the Parenteral Drug Association by a small group of pharmaceutical manufacturers who recognized the need for an organization to disseminate technical information within the industry. Today, coordinated through its headquarters in Bethesda, Maryland and its Training & Research Institute outside Baltimore, Maryland, PDA volunteers worldwide carry out its mission of promoting the exchange of rapidly evolving information on the latest technology and regulations concerning high-quality pharmaceutical production.
PDA is the recognized authoritative voice and leading technical organization in the field of parenteral science and technology. Through the development of Technical Reports, bulletins and responses to regulatory initiatives, PDA and its members influence the future course of pharmaceutical products technology.
With more than 10,500 individual members worldwide, PDA draws its strength from the technical expertise of its membership. Conferences, meetings and open forums bring together pharmaceutical manufacturers, suppliers, users, academics and regulatory officials to discuss issues of mutual interest. These exchanges of technical knowledge and expertise assist the advancement of pharmaceutical science and technology in the interest of public health.